The 2026 Asia-Pacific Healthy Longevity International Summit (APAC-LMIS), set to take place in Hong Kong from October 1-4, will gather around 2,000 researchers, clinicians, and policymakers to address the pressing challenge of translating geroscience into clinical practice. Organized by The Asia-Pacific Longevity Medicine Society (APLMS) and The Kitalys Institute, the summit aims to shift the focus from theoretical discussions to actionable strategies, emphasizing the theme “From Vision to Action.” This marks a significant maturation in the field, as stakeholders confront the realities of an aging population that demands immediate solutions rather than speculative future advancements.

The summit’s emphasis on regulatory hurdles, investment flows, and executive training highlights the necessity of building a robust infrastructure for longevity medicine. By positioning longevity clinics as pivotal translational interfaces, the event underscores their role in integrating emerging interventions and digital tools into routine care. This approach not only addresses the variability in protocols and standards across providers but also leverages the agility of clinics to adopt new modalities swiftly. The integration of AI-driven systems and personalized interventions into clinical settings represents a critical step toward achieving real-world impact.

The APAC-LMIS signifies a shift in research paradigms, moving from isolated scientific discovery to a more coordinated approach that aligns research, clinical practice, regulation, and investment. This evolution is crucial for fostering a sustainable clinical discipline capable of meeting the demands of an aging population. As the field transitions from ambition to alignment, the summit serves as a vital platform for establishing the professional standards and regulatory frameworks necessary to advance longevity therapeutics, ultimately paving the way for a more integrated and effective healthcare model.

Source: longevity.technology